Insider Buying: Geron (NASDAQ:GERN) EVP Acquires 12,000 Shares of Company Stock

Geron Corporation (NASDAQ:GERN – Get Free Report) EVP Timothy Williams bought 12,000 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was acquired at an average cost of $0.94 per share, for a total transaction of $11,280.00. Following the completion of the purchase, the executive vice president directly owned 12,000 shares in the company, valued at approximately $11,280. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Geron Trading Down 2.6%

Shares of GERN traded down $0.03 during trading on Monday, reaching $0.94. 9,306,519 shares of the company traded hands, compared to its average volume of 14,085,533. The stock has a 50-day simple moving average of $1.18 and a 200-day simple moving average of $1.40. The company has a quick ratio of 4.61, a current ratio of 6.31 and a debt-to-equity ratio of 0.53. Geron Corporation has a twelve month low of $0.84 and a twelve month high of $2.01. The stock has a market cap of $606.81 million, a PE ratio of -11.77 and a beta of 0.62.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GERN. Nantahala Capital Management LLC bought a new stake in shares of Geron in the 2nd quarter worth approximately $15,648,000. Bank of America Corp DE acquired a new position in Geron during the second quarter worth about $4,524,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Geron in the 2nd quarter worth approximately $2,982,000. Janus Henderson Group PLC grew its holdings in shares of Geron by 826.7% in the 1st quarter. Janus Henderson Group PLC now owns 2,218,196 shares of the biopharmaceutical company’s stock worth $3,304,000 after acquiring an additional 1,978,839 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Geron by 144.1% in the first quarter. Renaissance Technologies LLC now owns 1,799,521 shares of the biopharmaceutical company’s stock worth $2,681,000 after buying an additional 1,062,355 shares during the period. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on GERN. Needham & Company LLC lowered their price target on shares of Geron from $4.00 to $2.50 and set a “buy” rating for the company in a report on Wednesday, October 28th. Wedbush lowered their price objective on Geron to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, October 28th. Finally, Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.75.

View Our Latest Research Report on GERN

Geron Company Profile

(Get Free Report)

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.

Featured Articles

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.